Prolonged Protection From Bone Disease in Multiple Myeloma

Summary

Main hypothesis: Patients who continue zoledronic acid after year 2 have longer time until progression in bone disease compared to patients who stop treatment after two years? Secondary hypothesis: Serum will bone markers increase prior to progression in bone disease in the individual patient? Secondary hypothesis: Low-dose CT will detect more cases of osteolytic bone disease in Multiple Myeloma compared to conventional radiography

Timeline

Start

2015-01

Primary completion

2023-02-16

Completion

2023-02-16

Drugs

Indications